Bridgebio Pharma earnings were -$668.0M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest BBIO earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$167.4M, down 36.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BBIO reported annual earnings of -$535.8M, with -16.7% growth. The next BBIO earnings date is Jul 31, 2025.
What were Bridgebio Pharma's earnings last quarter?
On BBIO's earnings call on Invalid Date, Bridgebio Pharma (NASDAQ: BBIO) reported Q1 2025 earnings per share (EPS) of -$0.88, up 340% year over year. Total BBIO earnings for the quarter were -$167.42 million. In the same quarter last year, Bridgebio Pharma's earnings per share (EPS) was -$0.20.
The next BBIO earnings date is Invalid Date. Add BBIO to your watchlist to be reminded of Bridgebio Pharma's next earnings date.
Is Bridgebio Pharma profitable or losing money?
As of the last Bridgebio Pharma earnings report, Bridgebio Pharma is currently losing money. Bridgebio Pharma's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$667.97 million, a 24.1% increase year over year.
What was BBIO's earnings growth in the past year?
As of Bridgebio Pharma's earnings date in Invalid Date, Bridgebio Pharma's earnings has grown year over year. BBIO earnings in the past year totalled -$667.97 million.
What are Bridgebio Pharma's earnings expectations?
The current EPS estimate for Bridgebio Pharma's earnings report in Invalid Date is -$0.74.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.